Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.
BörsenkürzelHBIO
Name des UnternehmensHarvard Bioscience Inc
IPO-datumOct 21, 2013
CEOMr. John D. Duke
Anzahl der mitarbeiter330
WertpapierartOrdinary Share
GeschäftsjahresendeOct 21
Addresse84 October Hill Rd
StadtHOLLISTON
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl01746-1371
Telefon15088938999
Websitehttps://www.harvardbioscience.com/
BörsenkürzelHBIO
IPO-datumOct 21, 2013
CEOMr. John D. Duke
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten